SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.18 CNY | -0.28% |
|
+1.70% | -10.25% |
| Apr. 29 | Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 29 | RAAS Blood Products' 2023 Profit Falls 5% Despite 21% Revenue Growth | MT |
| Sales 2024 * | 8.84B 1.22B | Sales 2025 * | 9.77B 1.35B | Capitalization | 47.71B 6.59B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.34B 323M | Net income 2025 * | 2.66B 367M | EV / Sales 2024 * | 5.4 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.88 x |
| P/E ratio 2024 * |
20.2
x | P/E ratio 2025 * |
18
x | Employees | 3,254 |
| Yield 2024 * |
0.56% | Yield 2025 * |
0.6% | Free-Float | 69.53% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -0.28% | ||
| 1 week | +1.70% | ||
| Current month | +1.13% | ||
| 1 month | +1.13% | ||
| 3 months | +6.37% | ||
| 6 months | +4.66% | ||
| Current year | -10.25% |
1 week
7.01
7.32
1 month
6.667.32
Current year
5.938.60
1 year
5.938.68
3 years
4.988.68
5 years
4.9811.16
10 years
4.9826.67
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Xu
CEO | Chief Executive Officer | 60 | 11-12-31 |
Le Qi Chen
DFI | Director of Finance/CFO | 37 | 21-10-25 |
Wei Bing Hu
CHM | Chairman | 60 | 03-03-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 20-05-19 | |
Yue Wen Zheng
BRD | Director/Board Member | 62 | 07-04-26 |
David Ian Bell
BRD | Director/Board Member | 70 | 20-05-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.71% | 2 M€ | -14.14% | ||
| 0.69% | 2 M€ | -15.58% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 7.18 | -0.28% | 34,184,660 |
| 24-04-29 | 7.2 | +0.14% | 41,824,560 |
| 24-04-26 | 7.19 | -0.96% | 32,985,570 |
| 24-04-25 | 7.26 | +2.69% | 44,895,570 |
| 24-04-24 | 7.07 | +0.43% | 23,964,500 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin).
China accounts for 96.6% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.18
CNY
Average target price
7
CNY
Spread / Average Target
-2.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.25% | 6.59B | |
| -4.30% | 86.85B | |
| +2.76% | 40.16B | |
| -16.48% | 31.28B | |
| +57.86% | 25.27B | |
| -13.58% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.53% | 7.94B |
- Stock Market
- Equities
- 002252 Stock
